Evidence-based (S3) guideline on topical corticosteroids in pregnancy

British Journal of Dermatology

Volumn 165, Issue 5, 2011, Pages 943-952

  Chi, C C ^a   Kirtschig, G ^b   Aberer, W ^c   Gabbud, J P ^d   Lipozencic, J ^e   Karpati, S ^f   Haustein, U F ^g   Zuberbierff, T ^h   Wojnarowska, F ⁱ  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF GRAZ   (Austria)

^d Dermatology and Venereology   (Switzerland)

^e UNIVERSITY OF ZAGREB   (Croatia)

^f SEMMELWEIS UNIVERSITY   (Hungary)

^g UNIVERSITY OF LEIPZIG   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ALBUMIN; ALCLOMETASONE DIPROPIONATE; BETAMETHASONE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CLOBETASOL PROPIONATE; CLOBETASONE BUTYRATE; CORTICOSTEROID; DEXAMETHASONE; DIFLUCORTOLONE VALERATE; FLUDROXYCORTIDE; FLUOCINOLONE ACETONIDE; FLUOCINONIDE; FLUOCORTOLONE; FLUTICASONE; FLUTICASONE PROPIONATE; HYDROCORTISONE; HYDROCORTISONE BUTYRATE; METHYLPREDNISOLONE ACEPONATE; MOMETASONE FUROATE; PREDNISOLONE; TRANSCORTIN; TRIAMCINOLONE ACETONIDE; TERATOGENIC AGENT;

ADRENAL INSUFFICIENCY; ATOPIC DERMATITIS; CLEFT LIP; CLEFT PALATE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; ENVIRONMENTAL EXPOSURE; FACE MALFORMATION; FETUS DEATH; HUMAN; INTRAUTERINE GROWTH RETARDATION; OROFACIAL CLEFT; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; PSORIASIS; REVIEW; SIDE EFFECT; ANIMAL; BIOAVAILABILITY; CONGENITAL MALFORMATION; EVIDENCE BASED MEDICINE; FEMALE; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; PLACENTA; PREGNANCY COMPLICATION; SKIN DISEASE;

ABNORMALITIES, DRUG-INDUCED; ADMINISTRATION, CUTANEOUS; ADRENAL CORTEX HORMONES; ANIMALS; BIOLOGICAL AVAILABILITY; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MATERNAL EXPOSURE; PLACENTA; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS; SKIN DISEASES; TERATOGENS;

EID: 84856377466     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10513.x     Document Type: Review

References (62)

1. Berth-Jones J. Topical therapy. In: Rook's Textbook of Dermatology (Burns T, Breathnach SM, Cox N, eds), 7th edn. Oxford: Blackwell Publishing, 2004; 75.1-52.
2. Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2009; 4:CD002954.
3. Kirtschig G, Middleton P, Bennett C et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2010; 10:CD002292.
4. Marsland AM, Chalmers RJ, Hollis S et al. Interventions for chronic palmoplantar pustulosis. Cochrane Database Syst Rev 2006; 1: CD001433.
5. Al-Fares SI, Vaughan Jones S, Black MM. The specific dermatoses of pregnancy: a re-appraisal. J Eur Acad Dermatol Venereol 2001; 15:197-206. (Pubitemid 32898860)
6. Chi CC. Evidence-based assessment of the safety of topical cortico-steroids in pregnancy. DPhil thesis. Oxford: University of Oxford, 2009.
7. Hardy JR, Leaderer BP, Holford TR et al. Safety of medications prescribed before and during early pregnancy in a cohort of 81 975 mothers from the UK General Practice Research Database. Pharmaco-epidemiol Drug Saf 2006; 15:555-64. (Pubitemid 44336270)
8. Schirm E, Meijer WM, Tobi H et al. Drug use by pregnant women and comparable non-pregnant women in the Netherlands with reference to the Australian classification system. Eur J Obstet Gynecol Reprod Biol 2004; 114:182-8. (Pubitemid 38622080)
9. Bakker MK, Jentink J, Vroom F et al. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG 2006; 113:559-68.
10. Malm H, Martikainen J, Klaukka T et al. Prescription drugs during pregnancy and lactation - a Finnish register-based study. Eur J Clin Pharmacol 2003; 59:127-33. (Pubitemid 36793725)
11. Andrade SE, Gurwitz JH, Davis RL et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004; 191:398-407. (Pubitemid 39178690)
12. Olesen C, Sorensen HT, de Jong-van den Berg L et al. Prescribing during pregnancy and lactation with reference to the Swedish classification system. A population-based study among Danish women. The Euromap Group. Acta Obstet Gynecol Scand 1999; 78:686-92. (Pubitemid 29392672)
13. Colvin L, Slack-Smith L, Stanley FJ et al. Pharmacovigilance in pregnancy using population-based linked datasets. Pharmacoepidemiol Drug Saf 2009; 18:211-25.
14. Blume-Peytavi U, Blumeyer A, Tosti A et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol 2011; 164:5-15.
15. Phillips B, Ball C, Sackett D et al. Levels of Evidence. Oxford: Oxford Centre for Evidence-based Medicine, 2009, revised 2010. [WWW document]. Available at: http://www.cebm.net/index.aspx?o=1025 (last accessed 8 September 2011).
16. Nanda R, van der Linden FP, Jansen HW. Production of cleft palate with dexamethasone and hypervitaminosis A in rat embryos. Experientia 1970; 26:1111-12.
17. Nasjleti CE, Avery JK, Spencer HH et al. Tritiated cortisone distribution and induced cleft palate in mice. J Oral Ther Pharmacol 1967; 4:71-82.
18. Shah RM, Kilistoff A. Cleft palate induction in hamster fetuses by glucocorticoid hormones and their synthetic analogues. J Embryol Exp Morphol 1976; 36:101-8.
19. Walker BE. Induction of cleft palate in rabbits by several glucocorticoids. Proc Soc Exp Biol Med 1967; 125:1281-4.
20. Ballard PD, Hearney EF, Smith MB. Comparative teratogenicity of selected glucocorticoids applied ocularly in mice. Teratology 1977; 16:175-80. (Pubitemid 8215231)
21. Uno H, Eisele S, Sakai A et al. Neurotoxicity of glucocorticoids in the primate brain. Horm Behav 1994; 28:336-48.
22. Ikegami M, Jobe AH, Newnham J et al. Repetitive prenatal gluco-corticoids improve lung function and decrease growth in preterm lambs. Am J Respir Crit Care Med 1997; 156:178-84. (Pubitemid 27293185)
23. Yamada H, Nakano M, Ichihashi T et al. Fetal concentration after topical application of betamethasone 17,21-dipropionate (S-3440) ointment and teratogenesis in mice and rabbits. [Japanese]. Pharma-cometrics 1981; 21:645-55. (Pubitemid 11012637)
24. Taro Pharmaceuticals. Diflorasone Diacetate Cream Prescribing Information. Hawthorne: Taro Pharmaceuticals, 1999.
25. Narama I. Reproduction studies of diflorasone diacetate (DDA). IV. Teratogenicity study in rabbits by percutaneous administration. [Japanese]. Pharmacometrics 1984; 28:241-50. (Pubitemid 14009374)
26. Robertson DB, Maibach HI. Topical corticosteroids. Int J Dermatol 1982; 21:59-67. (Pubitemid 12148595)
27. Sifton DW, ed. Physicians' Desk Reference, 56th edn. Montvale: Medical Economics Company, 2002.
28. Günther C, Kecskes A, Staks T et al. Percutaneous absorption of methylprednisolone aceponate following topical application of Advantan lotion on intact, inflamed and stripped skin of male volunteers. Skin Pharmacol Appl Skin Physiol 1998; 11:35-42. (Pubitemid 28266288)
29. Turpeinen M, Mashkilleyson N, Bjorksten F et al. Percutaneous absorption of hydrocortisone during exacerbation and remission of atopic dermatitis in adults. Acta Derm Venereol 1988; 68:331-5.
30. Turpeinen M. Adrenocortical response to adrenocorticotropic hormone in relation to duration of topical therapy and percutaneous absorption of hydrocortisone in children with dermatitis. Eur J Pediatr 1989; 148:729-31. (Pubitemid 19186729)
31. Tschen EH, Bucko AD. Assessment of HPA-axis suppression with fluticasone cream 0.05% in patients with extensive psoriasis or eczema. Clin Drug Investig 1998; 16:111-16. (Pubitemid 28430054)
32. Kecskes A, Heger-Mahn D, Kuhlmann RK et al. Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointments with equal antiin-flammatory activity. J Am Acad Dermatol 1993; 29:576-80. (Pubitemid 23289559)
33. Higashi N, Katagiri K. Percutaneous absorption of 0.1% mometa-sone furoate ointment: fate, excretion and adrenocortical suppression. Skin Res 1990; 32:395-402. (Pubitemid 20289694)
34. Bressinck R, Williams J, Peets E. Comparison of the effect of mometasone furoate ointment 0.1%, and hydrocortisone ointment 1%, on adrenocortical function in psoriasis patients. Today's Ther Trends 1988; 5:25-34.
35. Mattison DR. Transdermal drug absorption during pregnancy. Clin Obstet Gynecol 1990; 33:718-27.
36. Daley-Yates PT, Kunka RL, Yin Y et al. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur J Clin Pharmacol 2004; 60:265-8. (Pubitemid 38916445)
37. Allen A, Down G, Newland A et al. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. Clin Ther 2007; 29:1415-20. (Pubitemid 47354209)
38. Corren J. Intranasal corticosteroids for allergic rhinitis: how do different agents compare? J Allergy Clin Immunol 1999; 104:S144-9. (Pubitemid 30249320)
39. Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am J Clin Dermatol 2002; 3:47-58. (Pubitemid 34158102)
40. Mirshahpanah P, Docke WD, Merbold U et al. Superior nuclear receptor selectivity and therapeutic index of methylprednisolone aceponate versus mometasone furoate. Exp Dermatol 2007; 16:753-61. (Pubitemid 47261867)
41. Sun K, Yang K, Challis JR. Glucocorticoid actions and metabolism in pregnancy: implications for placental function and fetal cardiovascular activity. Placenta 1998; 19:353-60. (Pubitemid 28327693)
42. Murphy BE, Clark SJ, Donald IR et al. Conversion of maternal cortisol to cortisone during placental transfer to the human fetus. Am J Obstet Gynecol 1974; 118:538-41.
43. Gitau R, Cameron A, Fisk NM et al. Fetal exposure to maternal cortisol. Lancet 1998; 352:707-8. (Pubitemid 28398713)
44. Gitau R, Fisk NM, Teixeira JM et al. Fetal hypothalamic-pituitary- adrenal stress responses to invasive procedures are independent of maternal responses. J Clin Endocrinol Metab 2001; 86:104-9. (Pubitemid 32109782)
45. Beitins IZ, Bayard F, Ances IG et al. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr 1972; 81:936-45.
46. Miller NM, Williamson C, Fisk NM et al. Infant cortisol response after prolonged antenatal prednisolone treatment. BJOG 2004; 111:1471-4. (Pubitemid 39665045)
47. Murphy VE, Fittock RJ, Zarzycki PK et al. Metabolism of synthetic steroids by the human placenta. Placenta 2007; 28:39-46. (Pubitemid 44734614)
48. Chi CC, Lee CW, Wojnarowska F, Kirtschig G. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev 2009; 3:CD007346.
49. Czeizel AE, Rockenbauer M. Population-based case-control study of teratogenic potential of corticosteroids. Teratology 1997; 56:335-40. (Pubitemid 28035180)
50. Mygind H, Thulstrup AM, Pedersen L et al. Risk of intrauterine growth retardation, malformations and other birth outcomes in children after topical use of corticosteroid in pregnancy. Acta Obstet Gynecol Scand 2002; 81:234-9. (Pubitemid 34264139)
51. Källén B. Maternal drug use and infant cleft lip/palate with special reference to corticoids. Cleft Palate Craniofac J 2003; 40:624-8. (Pubitemid 37429691)
52. Pradat P, Robert-Gnansia E, Di Tanna GL et al. First trimester exposure to corticosteroids and oral clefts. Birth Defects Res A Clin Mol Teratol 2003; 67:968-70. (Pubitemid 38018036)
53. Carmichael SL, Shaw GM, Ma C et al. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 2007; 197:585.e1-585.e7
54. Edwards MJ, Agho K, Attia J et al. Case-control study of cleft lip or palate after maternal use of topical corticosteroids during pregnancy. Am J Med Genet A 2003; 120:459-63. (Pubitemid 37063739)
55. Mahé A, Perret JL, Ly F et al. The cosmetic use of skin-lightening products during pregnancy in Dakar, Senegal: a common and potentially hazardous practice. Trans R Soc Trop Med Hyg 2007; 101:183-7. (Pubitemid 44835343)
56. Chi CC, Mayon-White RT, Wojnarowska FT. Safety of topical corti-costeroids in pregnancy: a population-based cohort study. J Invest Dermatol 2011; 131:884-91.
57. General Practice Research Database. The Database. London: GPRD Division of the Medicines and Healthcare Products Regulatory Agency (MHRA), 2007.
58. Hviid A, Molgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ 2011; 183:796-804.
59. Park-Wyllie L, Mazzotta P, Pastuszak A et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and metaanalysis of epidemiological studies. Teratology 2000; 62:385-92.
60. Gur C, Diav-Citrin O, Shechtman S et al. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol 2004; 18:93-101. (Pubitemid 38175451)
61. Mehta DK, ed. British National Formulary, 53rd edn. London: BMJ Publishing Group Ltd and RPS Publishing, 2007.
62. Luger TA, Lahfa M, Folster-Holst R et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat 2004; 15:169-78. (Pubitemid 39214578)